Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    Welcome !
    My account
    Logout

Trillium Therapeutics Inc (TRIL) Stock Forecast 2025 - AI Price Prediction & Analysis

Trillium Therapeutics Inc (TRIL) AI Stock Price Forecast & Investment Analysis

Trillium Therapeutics Inc Stock Price Chart and Technical Analysis

Loading Trillium Therapeutics Inc interactive price chart and technical analysis...

Trillium Therapeutics Inc (TRIL) - Comprehensive Stock Analysis & Investment Research

Deep dive into Trillium Therapeutics Inc's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Trillium Therapeutics Inc, including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Trillium Therapeutics Inc: Trillium Therapeutics Inc operates in the Manufacturing sector, making it an emerging small-cap investment.

Trillium Therapeutics Inc (Stock Symbol: TRIL) is a leading company in the Manufacturing sector , specifically operating within the Biological Product (except Diagnostic) Manufacturing industry.

The organization employs approximately 33 professionals worldwide .

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Trillium Therapeutics Inc's revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Trillium Therapeutics Inc:

Market Capitalization: $1899 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -28.5% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Trillium Therapeutics Inc stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For Trillium Therapeutics Inc: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Trillium Therapeutics Inc stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Trillium Therapeutics Inc's competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Trillium Therapeutics Inc: Market positioning analysis based on available financial and operational metrics.

Trillium Therapeutics Inc strategically competes in the highly dynamic Biological Product (except Diagnostic) Manufacturing marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

Trillium Therapeutics Inc (TRIL) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Trillium Therapeutics Inc stock analysis.

Loading Trillium Therapeutics Inc comprehensive fundamental analysis and insider trading data...

Deep dive into Trillium Therapeutics Inc's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Trillium Therapeutics Inc stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Trillium Therapeutics Inc: With a P/E ratio of -36.16, the market sees the stock as potentially undervalued.

P/E Ratio -36.16x
P/B Ratio 7.95x
Market Cap $1899M
EPS $-0.51
Book Value/Share $2.32
FCF/Share $-0.33
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Trillium Therapeutics Inc converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Trillium Therapeutics Inc: An ROE of -28.5% indicates room for improvement in shareholder value creation.

ROE -28.5%
ROA -19.9%
ROIC -29.1%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Trillium Therapeutics Inc's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Trillium Therapeutics Inc: A current ratio of 12.04 indicates strong liquidity.

Current Ratio 12.04x
Quick Ratio 11.54x
D/E Ratio 0.01x
Financial Leverage 1.17x
Interest Coverage -234.0x
Working Capital $277M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Trillium Therapeutics Inc's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Trillium Therapeutics Inc: Free cash flow of $-48M indicates cash challenges that need attention.

Operating Cash Flow $-47M
Free Cash Flow $-48M
CapEx/Sales 261.3%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Trillium Therapeutics Inc uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Trillium Therapeutics Inc:

Receivables Turnover 0.0x
Fixed Assets Turnover 0.0x
Days Sales Outstanding 10776 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Trillium Therapeutics Inc's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Trillium Therapeutics Inc:

Income Statement ($ Millions)
Operating Income $-57M
Net Income $-55M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 99%
Cash & Short-term Investments 94%
Total Liabilities 8%
Accounts Receivable 1%
Dividend & Shareholder Information
Shares Outstanding 103M

Latest Trillium Therapeutics Inc Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Trillium Therapeutics Inc (TRIL) stock price and investment outlook.

, source: Nasdaq

Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells. Its two lead molecules, TTI-622 and TTI-621, ...

, source: Insider Monkey

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our ...

, source: Nasdaq

Pfizer Inc said on Monday it would buy remaining shares of Trillium Therapeutics Inc it does not already own in a deal that values the cancer drug developer at $2.26 billion. Pfizer, which acquired a ...

, source: Reuters

Pfizer is taking its Covid-19 vaccine cash bounty and putting it to use . The U.S. drugmaker, valued at $273 billion at Friday's market close, on Monday agreed to buy Trillium Therapeutics for $2.3 ...

, source: The Financial

The FINANCIAL — Pfizer Inc and Trillium Therapeutics Inc. today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical stage ...

Trillium Therapeutics Inc Competitors & Peer Analysis - Manufacturing Sector

Comparative analysis of Trillium Therapeutics Inc against industry peers and competitors in the Manufacturing sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio

Frequently Asked Questions - Trillium Therapeutics Inc Stock Forecast

How accurate are Trillium Therapeutics Inc stock predictions?

Our AI model shows a 8500% Spearman correlation coefficient for TRIL predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Trillium Therapeutics Inc stock price forecasts?

Our analysis considers Trillium Therapeutics Inc's financial metrics, Manufacturing sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Trillium Therapeutics Inc a good investment in 2025?

Based on our AI analysis, Trillium Therapeutics Inc shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Trillium Therapeutics Inc forecasts updated?

Trillium Therapeutics Inc stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Trillium Therapeutics Inc Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Trillium Therapeutics Inc stock.

🎯 Get Premium Analysis 📊 Explore More Stocks

My Portfolio

Investment Dashboard

Loading your portfolio...